Formoprl-F 250 Dpi Caps is a combination medication containing Formoterol (6 mcg) and Fluticasone Propionate (250 mcg), designed for the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol is a long-acting beta2-adrenergic agonist that helps relax the muscles in the airways, improving airflow and making breathing easier. Fluticasone Propionate is a corticosteroid that reduces inflammation and swelling in the airways, preventing asthma attacks and exacerbations of COPD. Together, these active ingredients provide both immediate bronchodilation and long-term control of airway inflammation. Formoprl-F 250 Dpi Caps are typically administered via inhalation, allowing the medication to act directly on the lungs for rapid and effective relief. This combination therapy is intended for regular use to maintain symptom control and improve lung function, rather than for immediate relief of acute bronchospasm. Patients should use this medication exactly as prescribed by their healthcare provider and should not discontinue use abruptly without medical advice. Common side effects may include throat irritation, hoarseness, and oral thrush, which can be minimized by rinsing the mouth after inhalation. Formoprl-F 250 Dpi Caps offer a balanced approach to managing chronic respiratory conditions by combining bronchodilation and anti-inflammatory effects.